ArticleBMC ophthalmology2025
Takayasu retinopathy unveiling underlying Takayasu arteritis: a case report.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTakayasu arteritis (TAK) is a granulomatous large-vessel vasculitis of unknown etiology that predominantly affects the aorta and its branches. Ocular involvement occurs due to ischemia from vascular stenosis or occlusion and may present as transient visual loss, Takayasu retinopathy (TR), or ischemic optic neuropathy. In rare cases, ocular symptoms can be the initial manifestation, underscoring the importance of early recognition. CASE PRESENTATION: We report a 29-year-old male who presented with progressive blurring of vision, more marked in the left eye, for nine months. Systemic symptoms included presyncope and upper limb claudication. Ocular examination revealed multiple mid-peripheral microaneurysms and a wreath-like type 3 arteriovenous anastomosis near the left optic disc. Fundus fluorescein angiography showed 360° peripheral capillary nonperfusion, while Optical coherence tomography angiography demonstrated capillary dropout in the macular area in left eye. Carotid Doppler and CT angiography revealed diffuse mural thickening and near-total occlusion of major aortic arch branches. Raised C-reactive protein with negative anti-nuclear antibodies supported the diagnosis. Based on these findings, a diagnosis of TAK with stage 4 TR was made. The patient was treated with intravenous corticosteroids followed by immunosuppressants, along with panretinal photocoagulation and intravitreal ranibizumab in the left eye.
conclusionThis case highlights decreased vision as the initial and predominant manifestation of TAK, accompanied by systemic vascular symptoms. The presence of advanced TR with type 3 anastomosis reflected severe, chronic ischemia. Recognizing ocular signs in conjunction with systemic features such as claudication and syncope is vital for early diagnosis. Prompt systemic immunosuppression with adjunctive ocular interventions can prevent irreversible visual loss and systemic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.